Berk Michael, Fitzsimons Joanna, Lambert Timothy, Pantelis Christos, Kulkarni Jayashri, Castle David, Ryan Elizabeth W, Jespersen Sean, McGorry Pat, Berger Gregor, Kuluris Bill, Callaly Tom, Dodd Seetal
Department of Clinical and Biomedical Sciences, Barwon Health, The University of Melbourne, Geelong, Melbourne, Victoria, Australia.
CNS Drugs. 2007;21(2):117-27. doi: 10.2165/00023210-200721020-00003.
Clozapine is an important antipsychotic agent that has a unique profile of clinical benefits, but that has also been associated with several serious and potentially life-threatening safety concerns. In order to minimise the impact of haematological adverse events, health professionals treating patients with clozapine are currently required to register their patients on a centrally administered data network and to conform to strict protocols. The consensus statement documented in this article extends existing protocols by recommending monitoring of patients treated with clozapine for additional adverse effects during treatment. This consensus statement reflects the current practice at five major public psychiatric hospitals in Victoria, Australia, for the monitoring and management of clozapine-related adverse events, and has been implemented at these sites because of emerging safety concerns associating clozapine with cardiovascular and metabolic adverse effects.
氯氮平是一种重要的抗精神病药物，具有独特的临床益处，但也与一些严重且可能危及生命的安全问题相关。为了将血液学不良事件的影响降至最低，目前要求使用氯氮平治疗患者的医护人员将其患者登记到中央管理的数据网络中，并遵守严格的协议。本文记录的共识声明扩展了现有协议，建议在治疗期间监测使用氯氮平治疗的患者是否出现其他不良反应。这一共识声明反映了澳大利亚维多利亚州五家主要公立精神病医院目前对氯氮平相关不良事件进行监测和管理的做法，并且由于出现了将氯氮平与心血管和代谢不良反应相关联的安全问题，已在这些机构实施。
